Unmixed Infliximab Biosimilar from Canada
Infliximab biosimilar is a monoclonal antibody binding TNF-alpha, used for inflammatory conditions like rheumatoid arthritis. HTS 3002.13.0090 covers it as an unmixed, biotech-derived immunological product not in retail form. It qualifies per chapter notes as a protein regulating immunological processes.
Duty Rate — Canada → United States
100%
Rate breakdown
9903.04.60100%Except as provided in heading 9903.04.61, patented pharmaceutical articles as provided for in subdivisions (c) and (d) of U.S. note 40 to this subchapter
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
9903.05.900%Articles of aluminum, of steel or of copper or derivative aluminum or steel articles; passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; parts of passenger vehicles (sedans, sport utility vehicles, crossover utility vehicles, minivans and cargo vans) and light trucks; medium- and heavy-duty vehicles; parts of medium- and heavy-duty vehicles; wood products; patented pharmaceutical articles; and semiconductor articles, as provided in subdivision (f) of U.S. note 52 to this subchapter
Import Tips
• Provide biotech manufacturing details and sequence data to distinguish from chemical synthetics under Chapter 29
• Comply with CBP biotech import requirements, including advance notice for high-value shipments over $10,000
• Label clearly as 'unmixed' to prevent reclassification; dilution in water still counts as unmixed per chapter notes